Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis

详细信息    查看全文

• 作者：Marta Bonotto^a ; ^b ; ^{bonottomarta@gmail.com} ; Lorenzo Gerratana^a ; ^b ; Massimo Di Maio^c ; Carmine De Angelis^d ; Marika Cinausero^a ; ^b ; Stefano Moroso^b ; Monica Milano^d ; Brigida Stanzione^d ; Piera Gargiulo^d ; Donatella Iacono^b ; Alessandro Marco Minisini^b ; Mauro Mansutti^b ; Gianpiero Fasola^b ; Sabino De Placido^d ; Grazia Arpino^d ; Fabio Puglisi^a ; ^b
• 关键词：Metastatic breast neoplasms ; Drug therapy ; Chemotherapy ; Decision making ; Treatment outcome
• 刊名：The Breast
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：31
• 期：Complete
• 页码：114-120
• 全文大小：448 K
• 卷排序：31

文摘

Guidelines recommend endocrine therapy (ET) as first-line treatment for HER2-negative luminal-like metastatic breast cancer. In daily practice, chemotherapy (CT) is often used also outside of life-threatening disease. According to real life data of this study, clinicians preferred first-line CT in 38% of patients. Age and site of metastases influenced choice of first-line strategy (CT vs. ET). CT did not improve outcome compared to ET, as first-line treatment for HER2-negative luminal-like metastatic breast cancer.